Pharmacokinetics of ginsenoside Rb1 in lincomycin-induced gut microbiota dysbiosis rats
10.11665/j.issn.1000-5048.20160210
- VernacularTitle:人参皂苷Rb1在林可霉素诱导的菌群失调大鼠体内的药代动力学
- Author:
An KANG
1
;
Shengjie ZHANG
;
Jinjun SHAN
;
Liuqing DI
Author Information
1. 南京中医药大学药学院；江苏省儿童呼吸疾病(中医药)重点实验室；江苏省中药高效给药系统工程技术研究中心
- Publication Type:Journal Article
- Keywords:
ginsenoside Rb1;
pharmacokinetics;
gut microbiota dysbiosis;
lincomycin
- From:
Journal of China Pharmaceutical University
2016;47(2):182-187
- CountryChina
- Language:Chinese
-
Abstract:
Gut microbiota-mediated deglycosylationplays an important role in the metabolism of ginsenoside Rb1. Thus, a lincomycin-induced gut microbiota dysbiosis rat model was selected to explored the pharmacokinetics and deglycosylation metabolism of ginsenoside Rb1. An UPLC-MS/MS analytical method was developed to detect ginsenoside Rb1 and its deglycosylated metabolite, Rd in rat plasma. The triple quadruple mass spectrometer was set in negative electrospray ionization mode by multiple reaction monitoring. The method was validated to meet the requirements of biological applications, by evaluating specificity, linearity, lower limits of quantification(LLOQ), precision, accuracy, matrix effect, recovery and stability. Gut microbiota dysbiosis rats were induced by oral administration of lincomycin(5 000 mg/kg)for 7 continuous days. The in vitro and in vivo results reveal that the reduced β-D-glucosidase activity significantly decreases the Rd formation rate in lincomycin-induced gut microbiota dysbiosis rats, leading to the pharmacokinetic alteration of ginsenoside Rb1 and Rd in gut microbiota dysbiosis rats.
